Salesforce on Wednesday said former Gilead Sciences finance chief Robin Washington will join the software maker to become ...

AbbVie ( ABBV 0.64%) is a leader in biopharmaceuticals with a product portfolio spanning multiple therapeutic areas, ...

Gilead Sciences Inc. hit a new 52-week high, surpassing its previous peak of $99.45, which the company achieved on February ...

Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that Chief Executive Officer Todd Davis and Chief ...

As the role of CFOs continues to evolve, some companies are thinking of new ways to amplify their strategic mindsets. There ...

Gilead Sciences (GILD) closed at $99.65 in the latest trading session, marking a +1.69% move from the prior day.

The long-running HIV market rivalry between Gilead Sciences and GSK is about to turn a new page this year as Gilead looks to ...

To list the 10 Best Wide Moat Stocks to Invest In, we scanned through VanEck Morningstar Wide Moat ETF and some online ...

Gilead Sciences, Inc.'s strong sales growth in Veklury, Livdelzi, and Trodelvy shows promise for long-term financial success.

Beyond analysts' top -and-bottom-line estimates for Gilead (GILD), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ...

In a report released today, Brian Abrahams from RBC Capital maintained a Hold rating on Gilead Sciences (GILD – Research Report), with a price ...

RBC Capital analyst Brian Abrahams maintained a Hold rating on Neurocrine (NBIX – Research Report) yesterday and set a price target of $148.00.